熱門資訊> 正文
加拿大皇家银行资本市场（RBC Capital Markets）因最近抛售而升级神经分泌
2025-04-14 23:39
- Shares of Neurocrine Biosciences (NASDAQ:NBIX) gained on Monday after RBC Capital Markets upgraded the maker of movement disorder therapy Ingrezza, citing an attractive entry point given the recent market selloff.
- Broader sector selloff and market downside “has brought the stock to levels well below fundamental fair value, given an Ingrezza commercial franchise that we expect to be relatively solid and durable long term,” RBC analyst Brian Abrahams wrote.
- Upgrading the stock to Outperform from Sector Perform, Abrahams, however, adjusted his per-share target to $137 from $138, expecting volatility linked to the company’s Q1 results and its long-term exposure to Medicare drug price negotiations.
- The analyst added that Neurocrine’s (NASDAQ:NBIX) tariff-related exposure could be low relative to its rivals and noted that its sub-$100 share price “provides a good entry point for a stable, safe mid-cap biotech.”
More on Neurocrine Biosciences
- Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
- Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
- Neurocrine Biosciences authorizes $500M share repurchase program
- Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
- Seeking Alpha’s Quant Rating on Neurocrine Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
